Acute Hypersensitivity Reactions Associated With Administration of Crotalidae Polyvalent Immune Fab Antivenom

Cannon, Robert D.; Ruha, Anne‐Michelle; Kashani, John

doi:10.1016/j.annemergmed.2007.09.036

Cited by 75 publications

(47 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postproduction reports show a problematic unexplained recurrent coagulopathy in antivenom treated patients cited to at times be refractile to antivenom administration (Offerman et al, 2003), although there is yet more clinical observation and less published studies on antivenom use in the lessening of new coagulopathy cycles (Ruha et al, 2002). Recurrent swelling with C. helleri , but not others (Galan et al, 2004); and recurrence of swelling and defibrination syndrome for copperhead (Agkistrodon contortrix) envenomations have also been reported (Lavonas et al, 2004) as has hypersensitivity (Cannon et al, 2008). A variety of proteomic tools against of E-mail address: joseph.price@okstate.edu.…”

Section: Introductionmentioning

confidence: 91%

Microplate fluorescence protease assays test the inhibition of select North American snake venoms' activities with an anti-proteinase library

Price

2015

Toxicon

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 91%

Microplate fluorescence protease assays test the inhibition of select North American snake venoms' activities with an anti-proteinase library

Price

2015

Toxicon

View full text Add to dashboard Cite

“…These antivenoms are costly to produce and distribute; they must be delivered intravenously in an acute care facility; they have a relatively short shelf life; and they often induce side effects that are generally mild but occasionally serious. [16][17][18] Moreover, because patients seldom know the snake species that bit them, most antivenoms are polyvalent (polyspecific), and therefore less efficacious than monovalent forms. Thus, an alternative treatment should address the shortcomings of antivenoms.…”

Section: Introductionmentioning

confidence: 99%

C<SUB>60</SUB> Fullerenes as a Novel Treatment for Poisoning and Envenomation: A Proof-of-Concept Study for Snakebite

Darryl¹,

Hyun²,

William³

2016

j nanosci nanotechnol

View full text Add to dashboard Cite

Millions of poisonings and envenomations occur annually worldwide. When treatments for these conditions exist, they are often highly specific and may be costly or unavailable, especially in remote regions and developing countries. In cases of snake envenomation, mortality and severe morbidity occur in hundreds of thousands of cases annually. These tragic physiological sequelae result from the complex mixtures of protein toxins comprising snake venom. The current gold standard for snakebite treatment is to use a mixture of polyclonal antibodies, referred to as antivenom. While effective, antivenoms have severe limitations: they are costly to produce and distribute; they must be delivered in an acute care facility; they have a relatively short shelf life; and they often induce side effects that are generally mild but occasionally serious. Certain nanoparticles, in contrast, possess protein-binding and pharmacokinetic properties that make them a potentially low-cost and readily available adjunct or alternative to antivenom for treatment of systemically distributed toxins. We therefore conducted a proof-of-concept study to test the ability of C60 fullerene to neutralize rattlesnake venom in a cricket model. We injected approximate LD 50 doses of southern Pacific rattlesnake (Crotalus oreganus helleri) venom into crickets (Acheta domesticus). In the first of two experiments, crickets injected with C60 fullerene prior to envenomation experienced 15.7% and 25.0% higher rates of survival at 24 and 48 hr, respectively, compared to control crickets. In the second experiment, survival analysis confirmed that crickets protected with C60, regardless of C60 dose (1, 2, or 4 g/g cricket mass), experienced greater survival up to 60 hr and survived significantly longer than controls. C60 fullerene conferred significant protection against rattlesnake envenomation in a cricket model. Accordingly, C60 fullerene merits further consideration as a simple, low-cost treatment for snakebite and potentially many other forms of poisoning and envenomation.

show abstract

“…Cannon et al [9] reported hypersensitivity reactions in 5 (5.4%) of 93 patients treated with Fab antivenom in Phoenix. A meta-analysis by Schaeffer et al [10] estimated the probabilities of hypersensitivity or serum sickness as up to 8% and 13%, respectively.…”

mentioning

confidence: 98%

Factitious snake envenomation and narcotic-seeking behavior

Abdelmalek

Arroyo-Plasencia

Schwarz

et al. 2015

The American Journal of Emergency Medicine

View full text Add to dashboard Cite

Acute Hypersensitivity Reactions Associated With Administration of Crotalidae Polyvalent Immune Fab Antivenom

Cited by 75 publications

References 12 publications

Microplate fluorescence protease assays test the inhibition of select North American snake venoms' activities with an anti-proteinase library

Microplate fluorescence protease assays test the inhibition of select North American snake venoms' activities with an anti-proteinase library

C<SUB>60</SUB> Fullerenes as a Novel Treatment for Poisoning and Envenomation: A Proof-of-Concept Study for Snakebite

Factitious snake envenomation and narcotic-seeking behavior

Contact Info

Product

Resources

About